Seattle Genetics (SGEN) granted FDA orphan drug status for Mycois Fungoides
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Join SI Premium – FREE
Seattle Genetics (NASDAQ: SGEN) granted FDA orphan drug status for Mycois Fungoides
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aligos Therapeutics Inc. (ALGS) Presents Positive Data from the ALG-097558 Phase 1 Study
- HOOKIPA Pharma Inc. (HOOK) Receives FDA Clearance of INDA for HB-700
- Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
